Free Practice Questions for Iran Specialty Board Psychiatry

Exam-style questions and explanations by OpenExamPrep.

✓ No registration✓ No credit card

100+ Questions

100% Free

Loading practice questions...

Same family resources

Explore More Iran Medical Specialty Boards (دانشنامه تخصصی پزشکی / بورد تخصصی)

Continue into nearby exams from the same family. Each card keeps practice questions, study guides, flashcards, videos, and articles in one place.

Exam Review

Key Facts: Iran Specialty Board Psychiatry Exam

150

Total multiple-choice questions on the national written board certification examination

Secretariat for the Council for Medical and Specialized Education Guidelines

70% (105/150)

Minimum passing score required in the written exam to advance to the clinical patient interview

Sanjesh Pezeshki Specialty Board Examination Regulations

210 min

Total written examination duration, providing approximately 84 seconds per clinical question

Sanjesh Pezeshki Examination Administration Procedures

Negative marking: incorrect answers receive zero points without penalty

Iranian Medical Specialty Board Examination Rules

2 Stages

Examination structure: Stage 1 Written MCQ followed by Stage 2 Live Patient Interview & Oral Board

Council for Medical and Specialized Education

The Iranian Psychiatry Specialty Board Exam is a rigorous two-stage certification process administered by Sanjesh Pezeshki. Candidates must first achieve at least 70% (105/150) on the 240-minute written MCQ exam without negative marking to advance to the live clinical patient interview and oral board examination.

Sample Iran Specialty Board Psychiatry Practice Questions

Try these sample questions to review concepts for the Iran Specialty Board Psychiatry exam. Each question includes a detailed explanation. Start the interactive quiz above for the full 100+ question experience with AI tutoring.

1A 32-year-old man with treatment-resistant schizophrenia is initiating therapy with clozapine. According to standard clinical monitoring protocols, what is the minimum absolute neutrophil count (ANC) required to safely start clozapine therapy in the general psychiatric population, and what ANC threshold mandates immediate drug cessation?

A.Initiation threshold of at least 1,500/mcL; immediate cessation threshold if ANC drops below 1,000/mcL

B.Initiation threshold of at least 2,000/mcL; immediate cessation threshold if ANC drops below 1,500/mcL

C.Initiation threshold of at least 1,000/mcL; immediate cessation threshold if ANC drops below 500/mcL

D.Initiation threshold of at least 1,800/mcL; immediate cessation threshold if ANC drops below 1,200/mcL

Explanation: Standard clozapine monitoring guidelines require a baseline absolute neutrophil count of at least 1,500/mcL for the general population (or at least 1,000/mcL for individuals with confirmed benign ethnic neutropenia). Therapy must be immediately interrupted if the ANC falls below 1,000/mcL (severe neutropenia) to prevent life-threatening agranulocytosis. Regular hematologic monitoring is maintained weekly for the first 6 months, every 2 weeks for months 6 to 12, and monthly thereafter.

2A 45-year-old woman with bipolar I disorder maintained on lithium carbonate (serum level 0.8 mEq/L) develops acute osteoarthritis and starts an over-the-counter medication. Two weeks later, she presents with coarse hand tremor, ataxia, dysarthria, and vomiting. Serum lithium is 2.2 mEq/L. Which medication most likely precipitated this toxicity by decreasing renal lithium excretion?

A.Acetaminophen

B.Naproxen

C.Aspirin

D.Sulindac

Explanation: Nonsteroidal anti-inflammatory drugs (NSAIDs) such as naproxen, ibuprofen, and indomethacin inhibit renal prostaglandin synthesis, leading to decreased renal blood flow, reduced glomerular filtration, and increased proximal tubular reabsorption of lithium, frequently precipitating toxicity. In contrast, acetaminophen and low-to-moderate doses of aspirin do not meaningfully alter lithium clearance. Among NSAIDs, sulindac has a relatively lower propensity to increase lithium levels, but naproxen consistently induces significant elevations.

3A 24-year-old woman with bipolar I disorder is stabilized on sodium valproate. During pre-conception counseling, the psychiatrist discusses the major congenital malformations associated with first-trimester valproate exposure. Which structural malformation carries the highest specific relative risk following intrauterine valproate exposure?

A.Ebstein anomaly

B.Holoprosencephaly

C.Neural tube defects (spina bifida)

D.Transposition of the great vessels

Explanation: Valproate carries an approximately 1% to 2% risk of neural tube defects (primarily lumbosacral spina bifida and meningomyelocele), representing a 10- to 20-fold increased risk compared to the general population. In addition, valproate causes a characteristic fetal valproate syndrome, craniofacial abnormalities, cardiac defects, and significant long-term neurodevelopmental deficits, including reduced IQ and elevated autism spectrum risk. Ebstein anomaly is classically linked to first-trimester lithium exposure.

4A 29-year-old man with acute mania receives haloperidol 10 mg intramuscularly followed by oral haloperidol. Within 48 hours, he becomes mute, bedbound, and confused. Physical examination reveals a temperature of 39.8°C (103.6°F), blood pressure of 175/105 mmHg, heart rate of 124 beats/min, generalized lead-pipe muscle rigidity, and profuse diaphoresis. Serum creatine kinase is 28,000 U/L, and white blood cell count is 18,500/mcL. What is the definitive initial pharmacologic intervention after discontinuing haloperidol and initiating vigorous intravenous hydration?

A.Intravenous propranolol

B.Intravenous flumazenil

C.Oral cyproheptadine

D.Dantrolene combined with bromocriptine

Explanation: This patient presents with classic neuroleptic malignant syndrome (NMS), characterized by hyperthermia, extreme 'lead-pipe' rigidity, autonomic instability, delirium, and profound creatine kinase elevation following dopamine antagonist administration. Beyond immediate cessation of the causative agent and aggressive supportive care, specific pharmacotherapy involves dantrolene (a direct-acting skeletal muscle relaxant targeting the ryanodine receptor) and bromocriptine or amantadine (dopamine receptor agonists that overcome hypothalamic and nigrostriatal dopamine blockade). Cyproheptadine is the specific antidote for serotonin syndrome, not NMS.

5A 36-year-old man taking fluoxetine 40 mg daily ingests an over-the-counter cough syrup containing dextromethorphan and an herbal supplement containing St. John's wort. Several hours later, he develops agitation, ocular clonus, spontaneous ankle clonus, hyperreflexia in the lower extremities, shivering, and diarrhea. Which feature best differentiates this patient's condition from neuroleptic malignant syndrome?

A.Marked elevation of creatine kinase

B.Spontaneous or inducible neuromuscular clonus and hyperreflexia

C.Prominent hyperthermia and tachycardia

D.Altered mental status with acute delirium

Explanation: Spontaneous, ocular, or inducible clonus alongside lower extremity hyperreflexia is the clinical hallmark of serotonin syndrome according to the Hunter Serotonin Toxicity Criteria. In contrast, neuroleptic malignant syndrome is characterized by severe 'lead-pipe' rigidity and hyporeflexia or normal reflexes. Both conditions share autonomic instability, fever, mental status changes, and potential creatine kinase elevations, making the neuromuscular examination the critical differentiating factor.

6A 40-year-old man with schizophrenia has significant prediabetes (HbA1c 6.2%), central adiposity, and dyslipidemia. His psychiatrist wishes to switch his antipsychotic medication to an agent with the lowest propensity for causing further weight gain, insulin resistance, and atherogenic lipid abnormalities. Which second-generation antipsychotic has the most favorable metabolic profile?

A.Olanzapine

B.Quetiapine

C.Aripiprazole

D.Risperidone

Explanation: Aripiprazole (along with ziprasidone and lurasidone) has a very low propensity for weight gain, hyperglycemia, or dyslipidemia. Its mechanism as a partial D2 and 5-HT1A agonist with weak histamine H1 and 5-HT2C antagonism accounts for its metabolic neutrality. In contrast, olanzapine and clozapine carry the highest metabolic risk, followed by quetiapine and risperidone, which cause moderate weight gain and metabolic disruption largely through potent H1 and 5-HT2C receptor blockade.

7A 58-year-old woman treated with fluphenazine for 12 years exhibits persistent involuntary choreoathetoid movements of the tongue, lip smacking, and grimacing that worsen when she is distressed. A diagnosis of tardive dyskinesia is made. Which medication class is designated as first-line pharmacotherapy for this condition based on current clinical practice guidelines?

A.Centrally acting anticholinergics (such as trihexyphenidyl)

B.High-potency first-generation antipsychotics (such as haloperidol)

C.Dopamine receptor agonists (such as pramipexole)

D.Vesicular monoamine transporter 2 (VMAT2) inhibitors (such as valbenazine or deutetrabenazine)

Explanation: Vesicular monoamine transporter 2 (VMAT2) inhibitors, including valbenazine and deutetrabenazine, are FDA-approved, guideline-endorsed first-line pharmacotherapies for moderate-to-severe tardive dyskinesia. They selectively deplete presynaptic dopamine storage vesicles, mitigating postsynaptic dopamine receptor supersensitivity without blocking D2 receptors. In contrast, anticholinergic medications worsen tardive dyskinesia by disrupting the striatal dopamine-acetylcholine balance, and increasing the antipsychotic dose merely masks symptoms temporarily while exacerbating underlying neuropathology.

8Four hours after receiving an intramuscular injection of haloperidol 5 mg in the emergency department, an 18-year-old man develops sustained, painful retrocollis and involuntary upward deviation of both eyes (oculogyric crisis). Which immediate intervention is most appropriate?

A.Intravenous or intramuscular diphenhydramine or benztropine

B.Oral propranolol

C.Intramuscular flumazenil

D.Oral dantrolene

Explanation: The patient is experiencing an acute dystonic reaction (torticollis/retrocollis and oculogyric crisis), a sudden muscular spasm resulting from acute D2 receptor blockade leading to relative striatal cholinergic excess. Young males receiving high-potency first-generation antipsychotics are at highest risk. Parenteral administration of an anticholinergic agent (benztropine 1 to 2 mg IM/IV or diphenhydramine 25 to 50 mg IM/IV) rapidly rebalances dopamine-acetylcholine transmission, resolving the spasm within minutes.

9A 30-year-old woman with bipolar depression is currently taking sodium valproate 1,000 mg/day. Her psychiatrist decides to initiate lamotrigine as an adjunctive mood stabilizer. How must the standard lamotrigine titration schedule be modified in this patient to minimize the risk of Stevens-Johnson syndrome and toxic epidermal necrolysis?

A.Lamotrigine dose must be doubled compared to standard titration because valproate induces lamotrigine clearance

B.No dosage adjustment is necessary because valproate and lamotrigine do not interact pharmacokinetically

C.Lamotrigine starting dose and subsequent titration rate must be reduced by more than 50% because valproate inhibits lamotrigine glucuronidation

D.Lamotrigine should be administered once monthly via intramuscular depot injection to bypass hepatic metabolism

Explanation: Valproate is a potent inhibitor of uridine diphosphate glucuronosyltransferase (UGT1A4), the primary enzyme responsible for lamotrigine glucuronidation. Co-administration more than doubles the elimination half-life of lamotrigine and significantly raises its serum concentration. Therefore, when initiating lamotrigine in a patient taking valproate, the starting dose must be reduced from the standard 25 mg/day to 25 mg every other day (or 12.5 mg/day), and titration increments must be halved to avoid life-threatening cutaneous adverse reactions like Stevens-Johnson syndrome.

10A 35-year-old woman abruptly stops taking her prescribed antidepressant after 9 months of treatment. Within 36 hours, she experiences severe dizziness, electric-shock sensations in her extremities ('brain zaps'), nausea, vivid dreams, insomnia, and intense irritability. Which antidepressant is most likely responsible for this acute discontinuation syndrome?

A.Fluoxetine

B.Paroxetine

C.Vortioxetine

D.Agomelatine

Explanation: Paroxetine has a short elimination half-life (approximately 21 hours) and lacks active metabolites; it also possesses anticholinergic properties and non-linear pharmacokinetics. Abrupt discontinuation of paroxetine or venlafaxine causes the most rapid and severe antidepressant discontinuation syndrome (FINISH: Flu-like symptoms, Insomnia, Nausea, Imbalance, Sensory disturbances like brain zaps, Hyperarousal). In contrast, fluoxetine has a long half-life (parent drug 1-4 days, norfluoxetine 7-15 days), effectively self-tapering and rarely producing abrupt discontinuation symptoms.

About the Iran Specialty Board Psychiatry Exam

The Iranian Medical Specialty Board Examination in Psychiatry (آزمون دانشنامه تخصصی روانپزشکی - commonly known as 'Board-e Takhasosi-e Ravanshenakhti' or 'Daneshnameh Asab va Ravan') is the highest professional certifying examination in psychiatry in the Islamic Republic of Iran. Administered annually by the Secretariat for the Council for Medical and Specialized Education in conjunction with the National Center for Health Assessment (مرکز سنجش آموزش پزشکی - Sanjesh Pezeshki), successful completion confers full Board Certification (دانشنامه تخصصی), qualifying psychiatrists for academic faculty professorships, subspecialty fellowship training (such as child and adolescent psychiatry, addiction psychiatry, or psychosomatic medicine), and leadership of clinical departments across the country. The curriculum and written examination are based strictly on national board reference curricula designated by the Board Examining Board: Kaplan & Sadock's Comprehensive Textbook of Psychiatry (CTP), Kaplan & Sadock's Synopsis of Psychiatry, and DSM-5-TR, alongside clinical guidelines approved by the Iranian Psychiatric Association and Ministry of Health. The written examination tests 152 questions across six comprehensive domains: Psychopharmacology & Somatic Therapies (~22%), Psychotic Disorders & Schizophrenia Spectrum (~18%), Mood Disorders & Suicide Risk Assessment (~18%), Anxiety, Obsessive-Compulsive & Trauma/Stressor-Related Disorders (~15%), Substance-Related & Addictive Disorders & Consultation-Liaison Psychiatry (~15%), and Child/Adolescent Psychiatry, Neurocognitive Disorders & Personality Disorders (~12%). This practice question bank is an independent English-language MCQ study adaptation authored by OpenExamPrep. It contains 100 board-caliber clinical scenarios featuring rigorous diagnostic rationales and comprehensive distractor analyses to prepare psychiatry residents and international candidates for advanced board-level mastery. The official Iranian examination is delivered in Persian; this resource is an independent educational adaptation and is neither an official translation nor endorsed by Sanjesh Pezeshki.

Exam sponsor: Council for Medical and Specialized Education & National Center for Health Assessment (Sanjesh Pezeshki / مرکز سنجش آموزش پزشکی). The requirements and fees below concern the certification or admission exam, separate from our free practice resources.

Assessment

The Iranian Specialty Board Examination in Psychiatry is administered annually in late summer (Shahrivar / September) at central university assessment facilities in Tehran under the auspices of the Secretariat for the Council for Medical and Specialized Education and Sanjesh Pezeshki. The certification consists of two mandatory stages: Stage 1 is the Written Board Examination comprising 152 four-option multiple-choice questions administered over a single 240-minute session (no negative marking; passing cut score is 70%, or 105/150). Candidates who satisfy this threshold qualify for Stage 2, the Practical/Clinical Board Examination (آزمون شفاهی و مصاحبه بالینی), which assesses direct clinical patient interviewing, mental status examination, longitudinal psychodynamic and biopsychosocial formulation, diagnostic defense, and psychopharmacological treatment planning before a panel of academic board examiners.

Time Limit

240 minutes

Passing Score

70% of the written total (105 of 150 points)

Exam / Certification Fees

Set annually by the Ministry of Health and Medical Education, payable online via sanjeshp.ir during official board candidacy registration

Exam sponsor website

Fees, eligibility, and exam policies can change. Confirm them with the exam sponsor before applying or paying.

Official sources

Our practice resources: topics covered

We aim to reflect publicly available exam outlines and topic information in our study resources. Coverage, format, and difficulty may differ from the actual exam, and we cannot guarantee that every detail is accurate or current. Confirm exam requirements, fees, and policies with the official exam sponsor.

22%

Psychopharmacology & Somatic Therapies

Pharmacodynamics, receptor binding affinities (D2, 5-HT2A, H1, M1, alpha-1), pharmacokinetic interactions (CYP450 1A2, 2D6, 3A4), therapeutic drug monitoring for lithium, valproate, and carbamazepine; clozapine monitoring protocols (absolute neutrophil count parameters and myocarditis surveillance); management of extrapyramidal symptoms, tardive dyskinesia (VMAT2 inhibitors), neuroleptic malignant syndrome, and serotonin toxicity; electroconvulsive therapy (ECT) indications, seizure thresholds, stimulus dosing, and contraindications; repetitive transcranial magnetic stimulation (rTMS) protocols.

18%

Psychotic Disorders & Schizophrenia Spectrum

Diagnostic criteria (DSM-5-TR), first-rank Schneiderian symptoms, positive, negative, and cognitive symptom domains of schizophrenia; schizoaffective disorder (bipolar vs. depressive type, two-week psychotic requirement without prominent mood episode); delusional disorder subtypes (erotomanic, grandiose, persecutory, jealous, somatic); brief psychotic disorder and schizophreniform disorder; catatonia subtypes, Bush-Francis Catatonia Rating Scale, and the intravenous lorazepam challenge; differential diagnosis of secondary psychoses due to autoimmune encephalitis (anti-NMDA receptor encephalitis) and metabolic disorders.

18%

Mood Disorders & Suicide Risk Assessment

DSM-5-TR diagnostic criteria for major depressive episode, bipolar I disorder (manic episode requirements), bipolar II disorder (hypomanic episode and MDD requirement), cyclothymic disorder, and persistent depressive disorder (dysthymia); mixed features specifier, rapid cycling criteria; perinatal depression and postpartum psychosis; management of treatment-resistant depression (esketamine, augmentation strategies); comprehensive suicide risk formulation, protective factors, lethal means restriction, and emergency psychiatric admission thresholds.

15%

Anxiety, Obsessive-Compulsive & Trauma/Stressor-Related Disorders

Diagnostic features and psychopharmacological/psychotherapeutic management of panic disorder, agoraphobia, generalized anxiety disorder, social anxiety disorder (performance vs. generalized), and specific phobias; obsessive-compulsive disorder (OCD) neurocircuitry (cortico-striato-thalamo-cortical loops), high-dose SSRI strategies, exposure and response prevention (ERP); post-traumatic stress disorder (PTSD), acute stress disorder (timeframe: 3 days to 1 month), and adjustment disorders; somatic symptom disorder, illness anxiety disorder, and functional neurological disorder (conversion disorder).

15%

Substance-Related & Addictive Disorders & Consultation-Liaison Psychiatry

Diagnostic criteria and neurobiology of substance use disorders (opioids, alcohol, methamphetamine, cannabis, sedatives); management of acute alcohol withdrawal, CIWA-Ar protocols, delirium tremens, and Wernicke-Korsakoff encephalopathy; opioid substitution therapy (methadone and buprenorphine/naloxone) protocols; stimulant-induced psychosis; assessment and management of delirium (hyperactive, hypoactive, mixed) in medical-surgical units; psychiatric assessment for organ transplantation candidates; management of agitation in medically complex patients.

12%

Child & Adolescent Psychiatry, Neurocognitive Disorders & Personality Disorders

Diagnostic criteria, clinical course, and treatment of attention-deficit/hyperactivity disorder (ADHD: stimulants vs. non-stimulants), autism spectrum disorder (ASD), pediatric mood disorders, and disruptive behavior disorders; major and mild neurocognitive disorders (Alzheimer disease, vascular dementia, dementia with Lewy bodies, frontotemporal dementia); pseudodementia of depression versus true dementia; diagnostic criteria and psychotherapeutic management of Cluster A (paranoid, schizoid, schizotypal), Cluster B (borderline, antisocial, histrionic, narcissistic), and Cluster C (avoidant, dependent, obsessive-compulsive) personality disorders.

Preparing for the Iran Specialty Board Psychiatry Exam

What You Need to Know

Passing score: 70% of the written total (105 of 150 points)
Assessment: The Iranian Specialty Board Examination in Psychiatry is administered annually in late summer (Shahrivar / September) at central university assessment facilities in Tehran under the auspices of the Secretariat for the Council for Medical and Specialized Education and Sanjesh Pezeshki. The certification consists of two mandatory stages: Stage 1 is the Written Board Examination comprising 152 four-option multiple-choice questions administered over a single 240-minute session (no negative marking; passing cut score is 70%, or 105/150). Candidates who satisfy this threshold qualify for Stage 2, the Practical/Clinical Board Examination (آزمون شفاهی و مصاحبه بالینی), which assesses direct clinical patient interviewing, mental status examination, longitudinal psychodynamic and biopsychosocial formulation, diagnostic defense, and psychopharmacological treatment planning before a panel of academic board examiners.
Time limit: 240 minutes
Exam / certification fees: Set annually by the Ministry of Health and Medical Education, payable online via sanjeshp.ir during official board candidacy registration Official sources

Using Our Practice Resources

Work through all 100 available questions
Review every answer and explanation
Track weak areas and revisit them
Use our AI tutor for tough concepts

Iran Specialty Board Psychiatry: Suggested Study Strategy

1Master Psychopharmacology Receptor Binding Profiles & CYP Interactions: Dedicate substantial study time to the pharmacodynamics of second-generation antipsychotics (5-HT2A/D2 ratios, partial agonism at D2/5-HT1A, H1 and M1 binding affinities). Know the cytochrome P450 pathways (e.g., CYP1A2 induction by smoking affecting clozapine and olanzapine levels, CYP2D6 inhibition by fluoxetine and paroxetine, and carbamazepine's auto-induction).

2Memorize Therapeutic Drug Monitoring Windows & Toxicity Protocols: Know precise therapeutic serum levels for lithium (acute: 0.8–1.2 mEq/L; maintenance: 0.6–0.8 mEq/L; toxicity management and hemodialysis thresholds at 2.5 or 4.0 mEq/L), valproic acid (50–125 mcg/mL), and carbamazepine (4–12 mcg/mL). Review clozapine absolute neutrophil count (ANC) monitoring schedules and cardiac monitoring for myocarditis.

3Thoroughly Drill DSM-5-TR Duration and Exclusion Criteria: Board questions frequently pivot on specific temporal requirements (e.g., schizophrenia requiring 6 months of continuous signs with at least 1 month of active symptoms; schizophreniform disorder 1 to 6 months; brief psychotic disorder 1 day to 1 month; acute stress disorder 3 days to 1 month vs. PTSD >1 month; schizoaffective disorder requiring >=2 weeks of delusions/hallucinations without prominent mood symptoms).

4Practice Differentiating Neuropsychiatric Emergencies: Be prepared to distinguish Neuroleptic Malignant Syndrome (lead-pipe rigidity, hyporeflexia, fever, elevated CK, leukocytosis, recent dopamine antagonist) from Serotonin Syndrome (hyperreflexia, clonus, tremor, diaphoresis, GI distress, recent serotonergic agents) and Malignant Catatonia (waxy flexibility, posturing, autonomic instability responding to IV lorazepam).

5Pace Your Exam Strategy (240 Minutes for 152 Questions, Zero Negative Marking): With 240 minutes for 152 questions, you have 95 seconds per question. Because there is no negative marking, answer every question before time expires, never leaving any item blank.

Frequently Asked Questions

What is the Iranian Specialty Board Examination in Psychiatry (Daneshnameh Takhasosi Ravanshenakhti / Asab va Ravan)?

The Iranian Specialty Board Examination in Psychiatry (آزمون دانشنامه تخصصی روانپزشکی / بورد اعصاب و روان) is the definitive national certifying examination administered by the Secretariat for the Council for Medical and Specialized Education under the Ministry of Health and Medical Education (MOHME) through Sanjesh Pezeshki. Successful completion of both the written exam and clinical patient interview certifies candidates as board-certified psychiatrists, qualifying them for university faculty positions, subspecialty fellowship training, and independent consultant leadership.

What is the difference between the Certification Exam (Govahi / Arzyabi) and the Specialty Board Exam (Daneshnameh / Board)?

In Iran's medical residency training system, graduating residents take the Specialty Certificate Exam (گواهینامه تخصصی) at the conclusion of their residency to receive their specialist license and fulfill obligatory medical service. The National Specialty Board Examination (دانشنامه تخصصی / بورد), taken concurrently or subsequently, is a more rigorous competitive credential required for university academic faculty appointments, directing clinical training units, and pursuing subspecialty fellowships (e.g., child psychiatry, addiction medicine, psychosomatic medicine).

What is the structure of the written examination, and what is the passing cut score?

The written board examination consists of 152 four-option multiple-choice questions administered in Persian over 240 minutes (approximately 95 seconds per question). There is no negative marking for wrong answers. Candidates must achieve a score of at least 70% (105 points out of a written total of 150) to pass the written stage and qualify for the clinical patient interview and oral board examination.

What does Stage 2 (Clinical Patient Interview & Oral Board Examination) entail in Psychiatry?

Stage 2 is a rigorous practical examination comprising an unscripted live clinical interview with a psychiatric patient, followed by an oral defense before a panel of academic board examiners. The candidate is evaluated on patient engagement, conducting a thorough mental status examination, eliciting psychopathology, formulating a biopsychosocial and psychodynamic differential diagnosis, assessing suicide and violence risk, and defending an evidence-based pharmacotherapeutic and psychotherapeutic management plan.

Which textbooks and references are the primary sources for the Iranian Psychiatry Board?

The national psychiatric examining board designates Kaplan & Sadock's Comprehensive Textbook of Psychiatry (CTP), Kaplan & Sadock's Synopsis of Psychiatry (current edition), and the Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) as the official primary reference sources. Candidates are also expected to be familiar with national treatment protocols issued by the Iranian Psychiatric Association and the Ministry of Health.

Is this OpenExamPrep question bank an official Sanjesh Pezeshki study tool?

No. This question bank is an independent English-language multiple-choice practice adaptation authored by OpenExamPrep for conceptual review and board exam preparation. The official Iranian specialty board examination is administered in Persian by Sanjesh Pezeshki and the Council for Medical and Specialized Education. This resource is not affiliated with, endorsed by, or an official publication of Sanjesh Pezeshki or the Iranian Ministry of Health and Medical Education.

Free Practice Questions for Iran Specialty Board Psychiatry

Explore More Iran Medical Specialty Boards (دانشنامه تخصصی پزشکی / بورد تخصصی)

Iran Medical Specialty Board — Anesthesiology (بورد تخصصی بیهوشی)

Iran Medical Specialty Board — Cardiology (بورد تخصصی بیماری‌های قلب و عروق)

Iran Medical Specialty Board — Dermatology (بورد تخصصی پوست)

Iran Medical Specialty Board — Emergency Medicine (بورد تخصصی طب اورژانس)

Iran Medical Specialty Board — General Surgery (بورد تخصصی جراحی عمومی)

Iran Medical Specialty Board — Internal Medicine (بورد تخصصی بیماری‌های داخلی)